SOURCE: Theravance, Inc.
|
January 26, 2007 16:00 ET
Theravance to Host 2007 Investor R&D Day
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- January 26, 2007 -- Theravance, Inc. (NASDAQ: THRX)
announced today that it will host an Investor R&D Day on February 5, 2007
in New York City from noon to 4:00 pm ET to provide a comprehensive review
of preclinical and clinical development programs. The presentations will
cover all of Theravance's full discovery and development programs, except
Beyond Advair, with a focus on Theravance's approach to discovering,
developing, and commercializing medicines.
Theravance speakers will include Rick E Winningham, Chief Executive
Officer, Michael Kitt, MD, Senior Vice President, Development, David
Brinkley, Senior Vice President, Commercial Development, and project
leaders for Theravance's respiratory disease, bacterial infection, and
gastrointestinal motility dysfunction clinical programs as well as
Theravance's full discovery programs.
Guest speakers will include John Johanson, MD, Clinical Associate Professor
of Medicine, University of Illinois, and Ethan Rubinstein, MD, H.E. Sellers
Research Chair, Head, Section of Infectious Diseases, University of
Manitoba, Winnipeg, Canada.
Webcast Information
The presentation slides and live audio webcast can be accessed from
Theravance's web site at www.theravance.com. Listeners are encouraged to
visit the site at least 15 minutes prior to the scheduled presentation to
register, download and install any necessary audio software.
About Theravance
Theravance is a biopharmaceutical company with a pipeline of internally
discovered product candidates. Theravance is focused on the discovery,
development and commercialization of small molecule medicines across a
number of therapeutic areas including respiratory disease, bacterial
infections and gastrointestinal motility dysfunction. Of the five programs
in development, two are in late stage -- its telavancin program focusing on
treating serious Gram-positive bacterial infections with Astellas Pharma
Inc. and the Beyond Advair collaboration with GlaxoSmithKline. By
leveraging its proprietary insight of multivalency to drug discovery
focused on validated targets, Theravance is pursuing a
next-generation drug discovery strategy designed to discover superior
medicines in large markets. For more information, please visit the
company's web site at www.theravance.com.
THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE®
are registered trademarks of Theravance, Inc.
This press release contains and Theravance's 2007 Investor R&D Day
presentations will contain certain "forward-looking" statements as that
term is defined in the Private Securities Litigation Reform Act of 1995
regarding, among other things, statements relating to goals, plans,
objectives and future events. Theravance intends such forward-looking
statements to be covered by the safe harbor provisions for forward-looking
statements contained in Section 21E of the Exchange Act and the Private
Securities Litigation Reform Act of 1995. Examples of such statements
include statements relating to the goals, timing and expected results of
clinical and preclinical studies and regulatory review, statements
regarding the potential benefits and mechanisms of action of drug
candidates, the enabling capabilities of Theravance's approach to drug
discovery and its proprietary insights, statements concerning expectations
for product candidates through development and commercialization and
projections of revenue and other financial items. These statements are
based on the current estimates and assumptions of the management of
Theravance as of the date of this press release and the presentations and
are subject to risks, uncertainties, changes in circumstances, assumptions
and other factors that may cause the actual results of Theravance to be
materially different from those reflected in its forward-looking
statements. Important factors that could cause actual results to differ
materially from those indicated by such forward-looking statements include,
among others, risks related to delays or difficulties in commencing or
completing clinical and preclinical studies, the potential that results of
clinical or preclinical studies indicate product candidates are unsafe,
ineffective, inferior or not superior, delays or failure to achieve
regulatory approvals, and risks of collaborating with third parties to
develop and commercialize products. These and other risks are described in
greater detail under the heading "Risk Factors" contained in Item 1A of
Theravance's Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission (SEC) on November 6,
2006 and the risks discussed in our other filings with the SEC. Given these
uncertainties, you should not place undue reliance on these
forward-looking statements. Theravance assumes no obligation to update its
forward-looking statements.